Anterogen.Co.,Ltd. (065660.KQ)
KRW 16060.0
(-6.3%)
KRW 16060.0
(-6.3%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.5 Billion KRW | -1.38% |
| 2022 | 6.59 Billion KRW | -18.85% |
| 2021 | 8.12 Billion KRW | 95.64% |
| 2020 | 4.15 Billion KRW | 0.09% |
| 2019 | 4.14 Billion KRW | 14.98% |
| 2018 | 3.6 Billion KRW | -32.67% |
| 2017 | 5.35 Billion KRW | 9.42% |
| 2016 | 4.89 Billion KRW | 38.61% |
| 2015 | 3.53 Billion KRW | 92.57% |
| 2014 | 1.83 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.7 Billion KRW | 11.56% |
| 2024 Q1 | 1.53 Billion KRW | -15.22% |
| 2023 Q4 | 1.8 Billion KRW | 12.41% |
| 2023 Q3 | 1.6 Billion KRW | 4.35% |
| 2023 Q2 | 1.54 Billion KRW | -0.11% |
| 2023 FY | 6.5 Billion KRW | -1.38% |
| 2023 Q1 | 1.54 Billion KRW | -3.3% |
| 2022 Q2 | 1.77 Billion KRW | 6.55% |
| 2022 Q1 | 1.66 Billion KRW | -34.44% |
| 2022 Q4 | 1.59 Billion KRW | 2.72% |
| 2022 Q3 | 1.55 Billion KRW | -12.51% |
| 2022 FY | 6.59 Billion KRW | -18.85% |
| 2021 Q3 | 1.8 Billion KRW | -20.91% |
| 2021 Q2 | 2.28 Billion KRW | 54.06% |
| 2021 Q4 | 2.54 Billion KRW | 40.57% |
| 2021 FY | 8.12 Billion KRW | 95.64% |
| 2021 Q1 | 1.48 Billion KRW | 47.61% |
| 2020 Q4 | 1 Billion KRW | -8.25% |
| 2020 Q3 | 1.09 Billion KRW | -4.4% |
| 2020 Q2 | 1.14 Billion KRW | 26.92% |
| 2020 Q1 | 903.27 Million KRW | -12.41% |
| 2020 FY | 4.15 Billion KRW | 0.09% |
| 2019 FY | 4.14 Billion KRW | 14.98% |
| 2019 Q4 | 1.03 Billion KRW | -5.19% |
| 2019 Q3 | 1.08 Billion KRW | 4.35% |
| 2019 Q2 | 1.04 Billion KRW | 5.69% |
| 2019 Q1 | 986.28 Million KRW | 24.7% |
| 2018 Q3 | 840.93 Million KRW | -10.71% |
| 2018 Q4 | 790.9 Million KRW | -5.95% |
| 2018 Q1 | 1.03 Billion KRW | 9.0% |
| 2018 Q2 | 941.76 Million KRW | -8.88% |
| 2018 FY | 3.6 Billion KRW | -32.67% |
| 2017 Q1 | 1.94 Billion KRW | 122.17% |
| 2017 Q3 | 1.4 Billion KRW | 32.43% |
| 2017 Q2 | 1.06 Billion KRW | -45.47% |
| 2017 Q4 | 948.25 Million KRW | -32.47% |
| 2017 FY | 5.35 Billion KRW | 9.42% |
| 2016 Q3 | 1.18 Billion KRW | 57.72% |
| 2016 Q4 | 875.26 Million KRW | -26.17% |
| 2016 Q2 | 751.65 Million KRW | -63.93% |
| 2016 Q1 | 2.08 Billion KRW | 162.86% |
| 2016 FY | 4.89 Billion KRW | 38.61% |
| 2015 Q2 | 736.7 Million KRW | 17.02% |
| 2015 FY | 3.53 Billion KRW | 92.57% |
| 2015 Q3 | 1.37 Billion KRW | 86.41% |
| 2015 Q4 | 792.68 Million KRW | -42.28% |
| 2015 Q1 | 629.57 Million KRW | 0.0% |
| 2014 FY | 1.83 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | 84.848% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | 32.186% |
| BINEX Co., Ltd. | 154.82 Billion KRW | 95.802% |
| Bioneer Corporation | 263.23 Billion KRW | 97.531% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | 90.53% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -33.238% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -54.708% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 99.319% |
| Medy-Tox Inc. | 221.12 Billion KRW | 97.06% |
| Peptron, Inc. | 3.34 Billion KRW | -94.508% |
| Amicogen, Inc. | 159.9 Billion KRW | 95.935% |
| Genexine, Inc. | 4.42 Billion KRW | -46.844% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | 87.906% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | 80.963% |
| ALTEOGEN Inc. | 96.52 Billion KRW | 93.266% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 97.51% |
| SillaJen, Inc. | 3.93 Billion KRW | -64.999% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | 88.929% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | 61.907% |
| Genomictree Inc. | 3.41 Billion KRW | -90.176% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | 65.197% |
| EASY BIO,Inc. | 165.38 Billion KRW | 96.07% |
| GI Innovation, Inc. | 5.31 Billion KRW | -22.212% |